Omapatrilat was the first drug developed for the inhibition of both ACE and neprilysin pathways, but the results from the OVERTURE (Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events) trial did not show superior benefits when compared to angiotensin-converting enzyme inhibitor (ACEi) alone in lowering heart failure hospitalization rate or mortality risk [7]. Here, ACE is linked to heart failure.